{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:15:37Z","timestamp":1790748937257,"version":"4.1.0"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:sec><jats:title>Purpose of review<\/jats:title><jats:p>The purpose of this review is to summarize the pathophysiology of systemic mastocytosis, review the most recent clinical trials and drug development in systemic mastocytosis, with a specific focus on the advanced systemic mastocytosis subtypes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Recent findings<\/jats:title><jats:p>Systemic mastocytosis is a clonal neoplasm of mast cells that has had a number of successful therapeutic options being developed in the past few years. The first therapeutic agent to be Food and Drug Administration (FDA) approved in decades was midostaurin in 2017 with a 60% response rate % with improvement in both end-organ damage and symptoms. However, complete responses\/remissions with midostaurin have been elusive. Additional clinical trials of tyrosine kinase inhibitors that target the proto-oncogene receptor tyrosine kinase (<jats:italic toggle=\"yes\">KIT<\/jats:italic>) mutation show great promise. The two drugs with promising early clinical trial data include avapritinib and DCC-2618 with avapritinib showing potential to induce complete remissions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Summary<\/jats:title><jats:p>Therapies for systemic mastocytosis are in a stage of evolution with further elucidation of additional mutations associated with oncogenesis in addition to the most commonly described<jats:italic toggle=\"yes\">KIT<\/jats:italic>(give details), ongoing clinical trials could potentially with lead to further targeted therapy and increased complete responses and durable remissions.<\/jats:p><\/jats:sec>","DOI":"10.1097\/moh.0000000000000486","type":"journal-article","created":{"date-parts":[[2019,1,17]],"date-time":"2019-01-17T04:18:03Z","timestamp":1547698683000},"page":"112-118","source":"Crossref","is-referenced-by-count":7,"title":["Novel Approaches for Systemic Mastocytosis"],"prefix":"10.1097","volume":"26","author":[{"given":"Luke","family":"Fletcher","sequence":"first","affiliation":[{"name":"Knight Cancer Institute"},{"name":"Division of Hematology & Medical Oncology, Department of Medicine, Oregon Health & Science University, Portland, Oregon, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uma","family":"Borate","sequence":"additional","affiliation":[{"name":"Knight Cancer Institute"},{"name":"Division of Hematology & Medical Oncology, Department of Medicine, Oregon Health & Science University, Portland, Oregon, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230917","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"R2-20230917","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","article-title":"Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors","volume":"113","author":"Lim","year":"2009","journal-title":"Blood"},{"key":"R3-20230917","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.iac.2018.04.011","article-title":"Mast cell mediators of significance in clinical practice in mastocytosis","volume":"38","author":"Butterfield","year":"2018","journal-title":"Immunol Allergy Clin North Am"},{"key":"R4-20230917","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1111\/j.1365-2222.2007.02804.x","article-title":"Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA)","volume":"37","author":"Gonz\u00e1lez de Olano","year":"2007","journal-title":"Clin Exp Allergy"},{"key":"R5-20230917","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.jaci.2013.05.026","article-title":"Gastrointestinal manifestations in mastocytosis: a study of 83 patients","volume":"132","author":"Sokol","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"R6-20230917","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.iac.2014.02.001","article-title":"Neuropsychological features of adult mastocytosis","volume":"34","author":"Moura","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"key":"R7-20230917","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1136\/ard.2009.124511","article-title":"Systemic mastocytosis and bone involvement in a cohort of 75 patients","volume":"69","author":"Barete","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R8-20230917","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jmoldx.2010.10.004","article-title":"Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay","volume":"13","author":"Kristensen","year":"2011","journal-title":"J Mol Diagn"},{"key":"R9-20230917","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1182\/blood-2007-09-115477","article-title":"Oncogenic kit controls neoplastic mast cell growth through a Stat5\/PI3-kinase signaling cascade","volume":"112","author":"Harir","year":"2008","journal-title":"Blood"},{"key":"R10-20230917","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.leukres.2008.12.020","article-title":"Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis","volume":"33","author":"Vega-Ruiz","year":"2009","journal-title":"Leuk Res"},{"key":"R11-20230917","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1182\/blood.V126.23.349.349","article-title":"Additional mutations in SRSF2, ASXL1 and\/or RUNX1 identify a high risk group of patients with KIT D816V+ advanced systemic mastocytosis","volume":"126","author":"Jawhar","year":"2015","journal-title":"Blood"},{"key":"R12-20230917","doi-asserted-by":"crossref","first-page":"5812","DOI":"10.1182\/blood-2010-08-292144","article-title":"How I treat patients with advanced systemic mastocytosis","volume":"116","author":"Valent","year":"2010","journal-title":"Blood"},{"key":"R13-20230917","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S0140-6736(16)31403-9","article-title":"Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study","volume":"389","author":"Lortholary","year":"2017","journal-title":"Lancet"},{"key":"R15-20230917","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1046\/j.1365-2141.2003.04575.x","article-title":"Diagnosis and treatment of systemic mastocytosis: state of the art","volume":"122","author":"Valent","year":"2003","journal-title":"Br J Haematol"},{"key":"R16-20230917","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2362.2007.01807.x","article-title":"Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria","volume":"37","author":"Valent","year":"2007","journal-title":"Eur J Clin Invest"},{"key":"R17-20230917","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1182\/blood-2012-09-458521","article-title":"International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis","volume":"121","author":"Gotlib","year":"2013","journal-title":"Blood"},{"key":"R18-20230917","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ajh.21561","article-title":"Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine","volume":"84","author":"Lim","year":"2009","journal-title":"Am J Hematol"},{"key":"R19-20230917","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1046\/j.1365-2141.2002.03944.x","article-title":"Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients","volume":"119","author":"Casassus","year":"2002","journal-title":"Br J Haematol"},{"key":"R20-20230917","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1182\/blood-2014-12-614743","article-title":"Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis","volume":"126","author":"Barete","year":"2015","journal-title":"Blood"},{"key":"R21-20230917","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/sj.bmt.1705245","article-title":"A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis","volume":"37","author":"Nakamura","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"R22-20230917","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1200\/JCO.2014.55.2018","article-title":"Hematopoietic stem-cell transplantation for advanced systemic mastocytosis","volume":"32","author":"Ustun","year":"2014","journal-title":"J Clin Oncol"},{"key":"R23-20230917","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 Mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"key":"R24-20230917","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1182\/bloodadvances.2017011080","article-title":"Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis","volume":"2","author":"Stone","year":"2018","journal-title":"Blood Adv"},{"key":"R25-20230917","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1182\/blood-2005-04-1568","article-title":"Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816 V KIT mutation","volume":"106","author":"Gotlib","year":"2005","journal-title":"Blood"},{"key":"R26-20230917","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N Engl J Med"},{"key":"R28-20230917","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/leu.2017.234","article-title":"Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial","volume":"32","author":"DeAngelo","year":"2018","journal-title":"Leukemia"},{"key":"R29-20230917","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2018-0222","article-title":"FDA approval summary: midostaurin for the treatment of advanced systemic mastocytosis","author":"Kasamon","year":"2018","journal-title":"Oncologist"},{"key":"R30-20230917","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jaci.2018.06.003","article-title":"Midostaurin in patients with indolent systemic mastocytosis: an open-label phase 2 trial","volume":"142","author":"van Anrooij","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"(Suppl 1)","key":"R31-20230917","article-title":"Clinical activity in a phase 1 study of BLU-285, a potent, highly selective inhibitor of KIT D816V in advanced systemic mastocytosis. Clinical Activity in a Phase 1 Study of Blu-285, a potent, highly-selective inhibitor of KIT D816V in advanced systemic mastocytosis (AdvSM)","volume":"130","author":"DeAngelo","year":"2017","journal-title":"Blood"},{"key":"R33-20230917","doi-asserted-by":"crossref","first-page":"799","DOI":"10.3324\/haematol.2017.179895","article-title":"The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis","volume":"103","author":"Schneeweiss","year":"2018","journal-title":"Haematologica"},{"key":"R35-20230917","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1182\/blood-2017-01-764423","article-title":"Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers","volume":"130","author":"Jawhar","year":"2017","journal-title":"Blood"}],"container-title":["Current Opinion in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00062752-201903000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T04:31:12Z","timestamp":1720931472000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00062752-201903000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/moh.0000000000000486","relation":{},"ISSN":["1065-6251","1531-7048"],"issn-type":[{"value":"1065-6251","type":"print"},{"value":"1531-7048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3]]}}}